Alumis Inc.

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. The company’s current pipeline centers on oral TYK2 inhibitors designed to address conditions such as plaque psoriasis and systemic lupus erythematosus, alongside a CNS-penetrant TYK2 program being studied for neuroinflammatory and neurodegenerative disorders. Alumis is also advancing lonigutamab, an antibody therapy aimed at thyroid eye disease, and additional discovery-stage programs built around its precision data analytics platform. The company works across immunology and inflammation, combining drug discovery, clinical development, and translational science to build treatments that may be used as monotherapy or in combination settings. Headquartered in South San Francisco, California, Alumis operates as a focused biotech platform in the autoimmune and immune dysfunction market.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Martin Babler Ph.D.

Employees

237

Headquarters

South San Francisco, CA, United States

Website

www.alumis.com